The mm Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mm Hub cannot guarantee the accuracy of translated content. The mm and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Multiple Myeloma Hub is an independent medical education platform, sponsored by Bristol Myers Squibb, GSK, Johnson & Johnson, Pfizer, Roche and Sanofi. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View mm content recommended for you
HOVON 143: ixazomib, daratumumab & low-dose dexamethasone for unfit & frail patients with NDMM
Featured:
Sonja ZweegmanThe Multiple Myeloma Hub are pleased to present a series of expert interviews from the 61st American Society of Hematology (ASH) meeting in Orlando, US. In this video, Sonja Zweegman, Amsterdam UMC – VU University, Amsterdam, NL, discusses the HOVON 143 study: ixazomib, daratumumab & low-dose dexamethasone for unfit & frail patients with NDMM.
Sonja Zweegman talks about the results of the HOVON 143 trial, that focused on unfit & frail patients. She discusses the survival and response rate of patients that were treated with ixazomib, daratumumab & low-dose dexamethasone combination.
HOVON 143: ixazomib, daratumumab & low-dose dexamethasone for unfit & frail patients with NDMM